One study demonstrated that EGFR‐targeted BiTEs produced by CAR‐T cells could induce effective and specific anti‐tumor activity against heterogeneous tumors and mitigate against the effects of EGFRvIII which causes antigen loss. This evidence concerns the gene EGFR and neoplasm.